サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1582704

非侵襲的出生前検査 (NIPT) の世界市場：産業分析・規模・シェア・成長・動向・予測 (2024-2033年)

Non-invasive Prenatal Testing (NIPT) Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 136 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
非侵襲的出生前検査 (NIPT) の世界市場：産業分析・規模・シェア・成長・動向・予測 (2024-2033年)
出版日: 2024年10月30日
発行: Persistence Market Research
ページ情報: 英文 136 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の非侵襲的出生前検査 (NIPT) の市場を調査し、市場の定義と概要、市場促進要因・抑制要因、各種動向、市場機会、課題、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、主要企業のプロファイルなどをまとめています。

主な洞察

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義
  • 市場分類

第3章 世界の非侵襲的出生前検査市場の分析シナリオ

  • 価格分析
  • 市場・予測
    • 市場規模・前年比成長率
  • 市場概要

第4章 市場力学

  • マクロ経済要因
  • 促進要因
  • 抑制要因
  • 成長機会
  • 動向
  • 規制シナリオ
  • 償還シナリオ
  • 製品比較マトリックス
  • 陽性的中度の比較

第5章 世界の非侵襲的出生前検査市場の分析・予測：検査別

  • BPS分析
  • 前年比成長予測
  • 市場規模の予測
    • パネル1検査
    • パネル2検査
    • パネル3検査
  • 市場の魅力

第6章 世界の非侵襲的出生前検査市場の分析・予測：エンドユーザー別

  • BPS分析
  • 前年比成長予測
  • 市場規模の予測
    • 病院
    • 診断ラボ
    • 産科センター
  • 市場の魅力

第7章 世界の非侵襲的出生前検査市場の分析・予測：地域別

  • BPS分析
  • 前年比成長予測
  • 市場規模の予測
    • 北米
    • ラテンアメリカ
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
  • 市場の魅力

第8章 北米の非侵襲的出生前検査市場の分析・予測

  • 市場規模の予測：検査別
  • 市場規模の予測：エンドユーザー別
  • 市場規模の予測：国別
  • 市場の魅力分析
  • 注目の動向

第9章 ラテンアメリカの非侵襲的出生前検査市場の分析・予測

  • 市場規模の予測：検査別
  • 市場規模の予測：エンドユーザー別
  • 市場規模の予測：国別
  • 市場の魅力分析
  • 注目の動向

第10章 欧州の非侵襲的出生前検査市場の分析・予測

  • 市場規模の予測：検査別
  • 市場規模の予測：エンドユーザー別
  • 市場規模の予測：国別
  • 市場の魅力分析
  • 注目の動向

第11章 アジア太平洋の非侵襲的出生前検査市場の分析・予測

  • 市場規模の予測：検査別
  • 市場規模の予測：エンドユーザー別
  • 市場規模の予測：国別
  • 市場の魅力分析
  • 注目の動向

第12章 中東・アフリカの非侵襲的出生前検査市場の分析・予測

  • 市場規模の予測：検査別
  • 市場規模の予測：エンドユーザー別
  • 市場規模の予測：国別
  • 市場の魅力分析
  • 注目の動向

第13章 競合情勢

  • 競合ダッシュボード
  • 企業プロファイル
    • Ariosa Diagnostics, Inc.
    • Berry Genomics Co. Ltd.
    • BGI Diagnostics
    • Illumina, Inc.
    • LifeCodexx AG
    • Natera, Inc.
    • Sequenom Laboratories
    • Quest Diagnostics, Inc.

第14章 前提・頭字語

第15章 調査手法

目次
Product Code: PMRREP11218

Persistence Market Research has recently released a comprehensive report on the global Non-invasive Prenatal Testing (NIPT) market. This report provides an in-depth evaluation of critical market dynamics, including drivers, trends, opportunities, and challenges, delivering detailed insights into the market structure.

Key Insights:

  • NIPT Market Size (2024E): USD 7.1 Bn
  • Projected Market Value (2031F): USD 16.2 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 12.5%

NIPT Market - Report Scope:

Non-invasive prenatal testing (NIPT) is a revolutionary technology used in prenatal screening for detecting chromosomal abnormalities in a fetus. Unlike invasive testing methods, NIPT uses cell-free fetal DNA (cffDNA) from the mother's blood, providing accurate results with minimal risk. This technology is essential for expectant mothers and healthcare providers, offering early insights into genetic abnormalities such as Down syndrome, Edwards syndrome, and Patau syndrome. The NIPT market caters to diagnostic laboratories, hospitals, clinics, and various healthcare institutions, with growth fueled by increasing awareness of genetic disorders, advances in testing technology, and a rising preference for early non-invasive diagnostics.

Market Growth Drivers:

The global NIPT market is driven by several key factors. Increasing awareness of genetic disorders, especially among expectant parents, is a significant growth catalyst. Advances in DNA sequencing technology and the availability of high-accuracy screening are increasing the adoption of NIPT. Additionally, the demand for safe, non-invasive prenatal screening continues to grow as more healthcare providers advocate for early detection of chromosomal abnormalities. The rising maternal age and associated risk of genetic disorders also contribute to the increased utilization of NIPT services, while the advancements in AI and bioinformatics improve the precision and reliability of testing.

Market Restraints:

While the NIPT market shows promising growth, it faces challenges such as high test costs and limited insurance coverage in certain regions, which can impact accessibility for a broader population. Regulatory constraints in specific countries and ethical concerns regarding genetic testing also limit market expansion. Moreover, false-positive and false-negative results, though rare, may raise concerns regarding test accuracy. Addressing these challenges requires industry players to focus on cost-effective testing solutions, raise awareness of the safety and efficacy of NIPT, and work closely with policymakers to establish clear regulatory guidelines for market entry.

Market Opportunities:

The NIPT market presents notable opportunities fueled by ongoing research and technological advancements. Increasing R&D investments, especially in high-sensitivity and specific testing methods, offer potential for new product development and market expansion. The market is also likely to benefit from greater integration of NIPT with genetic counseling services, providing a holistic approach to prenatal care. Expanding NIPT into emerging markets, where demand is growing for modern healthcare solutions, also presents a significant growth area. Strategic partnerships with insurance companies, hospitals, and research institutions can further enhance market penetration and create new revenue streams.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the global NIPT market?
  • Which regions are witnessing the fastest adoption of NIPT solutions?
  • How do technological advancements influence the competitive landscape of the NIPT market?
  • Who are the leading players in the NIPT market, and what are their key strategies?
  • What are the emerging trends and future prospects in the global NIPT market?

Competitive Intelligence and Business Strategy:

Leading players in the global NIPT market, including Illumina Inc., Natera Inc., and Roche Diagnostics, focus on continuous innovation and strategic partnerships to maintain a competitive edge. These companies invest heavily in R&D to enhance the accuracy and reduce the cost of NIPT solutions. Strategic collaborations with healthcare providers and institutions strengthen market accessibility and foster product adoption. Emphasis on clinical trials, regulatory approvals, and sustainable marketing strategies also contributes to market growth and builds consumer confidence in the safety and efficacy of NIPT.

Key Companies Profiled:

  • Ariosa Diagnostics, Inc.
  • Berry Genomics Co. Ltd.
  • BGI Diagnostics
  • Illumina, Inc.
  • LifeCodexx AG
  • Natera, Inc.
  • Sequenom Laboratories
  • Quest Diagnostics, Inc.
  • Others

Non-invasive Prenatal Testing (NIPT) Market Industry Segmentation:

By Test Type

  • Panel 1 Tests
  • Panel 2 Tests
  • Panel 3 Tests

By End User

  • Hospitals
  • Diagnostic Centers
  • Maternity Clinics

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Table of Contents

1. Executive Summary

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy

3. Global Non-Invasive Prenatal Testing Market Analysis Scenario

  • 3.1. Pricing Analysis
    • 3.1.1. Pricing Assumptions
    • 3.1.2. Price Projections Per Region
  • 3.2. Market Size (US$ Mn) and Forecast
    • 3.2.1. Market Size and Y-o-Y Growth
    • 3.2.2. Absolute $ Opportunity
  • 3.3. Market Overview
    • 3.3.1. Testing Decision Flow Chart

4. Market Dynamics

  • 4.1. Macro-economic Factors
  • 4.2. Drivers
    • 4.2.1. Supply Side
    • 4.2.2. Demand Side
  • 4.3. Restraints
  • 4.4. Growth Opportunities
  • 4.5. Trends
  • 4.6. Regulatory Scenario
  • 4.7. Reimbursement Scenario
  • 4.8. Product Comparison Matrix
  • 4.9. Positive Predictive Value (PPV) Comparison

5. Global Non-Invasive Prenatal Testing Market Analysis and Forecasts, By Test

  • 5.1. Introduction
  • 5.2. Basis Point Share (BPS) Analysis By Test Type
  • 5.3. Y-o-Y Growth Projections By Test Type
  • 5.4. Market Value Forecast By Test, 2024-2033
    • 5.4.1. Panel 1 Test
    • 5.4.2. Panel 2 Test
    • 5.4.3. Panel 3 Test
  • 5.5. Market Attractiveness By Test

6. Global Non-Invasive Prenatal Testing Market Analysis and Forecasts, By End User

  • 6.1. Introduction
  • 6.2. Basis Point Share (BPS) Analysis By End User
  • 6.3. Y-o-Y Growth Projections By End User
  • 6.4. Market Value Forecast By End User, 2024-2033
    • 6.4.1. Hospitals
    • 6.4.2. Diagnostic Laboratories
    • 6.4.3. Maternity Centers
  • 6.5. Market Attractiveness By End User

7. Global Non-Invasive Prenatal Testing Market Analysis and Forecasts, By Region

  • 7.1. Basis Point Share (BPS) Analysis By Region
  • 7.2. Y-o-Y Growth Projections By Region
  • 7.3. Market Value Forecast By Region
    • 7.3.1. North America
    • 7.3.2. Latin America
    • 7.3.3. Europe
    • 7.3.4. Asia Pacific
    • 7.3.5. Middle East and Africa
  • 7.4. Market Attractiveness By Region

8. North America Non-Invasive Prenatal Testing Market Analysis and Forecast

  • 8.1. Introduction
    • 8.1.1. Basis Point Share (BPS) Analysis By Country
    • 8.1.2. Y-o-Y Growth Projections By Country
  • 8.2. Market Value Forecast By Test, 2024-2033
    • 8.2.1. Panel 1 Test
    • 8.2.2. Panel 2 Test
    • 8.2.3. Panel 3 Test
  • 8.3. Market Value Forecast By End User, 2024-2033
    • 8.3.1. Hospitals
    • 8.3.2. Diagnostic Laboratories
    • 8.3.3. Maternity Centers
  • 8.4. Market Value Forecast By Country, 2024-2033
    • 8.4.1. US
    • 8.4.2. Canada
  • 8.5. Market Attractiveness Analysis
    • 8.5.1. By Test
    • 8.5.2. By End User
    • 8.5.3. By Country
  • 8.6. Prominent Trends

9. Latin America Non-Invasive Prenatal Testing Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Basis Point Share (BPS) Analysis By Country
    • 9.1.2. Y-o-Y Growth Projections By Country
  • 9.2. Market Value Forecast By Test, 2024-2033
    • 9.2.1. Panel 1 Test
    • 9.2.2. Panel 2 Test
    • 9.2.3. Panel 3 Test
  • 9.3. Market Value Forecast By End User, 2024-2033
    • 9.3.1. Hospitals
    • 9.3.2. Diagnostic Laboratories
    • 9.3.3. Maternity Centers
  • 9.4. Market Value Forecast By Country, 2024-2033
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Test
    • 9.5.2. By End User
    • 9.5.3. By Country
  • 9.6. Prominent Trends

10. Europe Non-Invasive Prenatal Testing Market Analysis and Forecast

  • 10.1.Introduction
    • 10.1.1. Basis Point Share (BPS) Analysis By Country
    • 10.1.2. Y-o-Y Growth Projections By Country
  • 10.2.Market Value Forecast By Test, 2024-2033
    • 10.2.1. Panel 1 Test
    • 10.2.2. Panel 2 Test
    • 10.2.3. Panel 3 Test
  • 10.3.Market Value Forecast By End User, 2024-2033
    • 10.3.1. Hospitals
    • 10.3.2. Diagnostic Laboratories
    • 10.3.3. Maternity Centers
  • 10.4.Market Value Forecast By Country, 2024-2033
    • 10.4.1. UK
    • 10.4.2. France
    • 10.4.3. Germany
    • 10.4.4. Spain
    • 10.4.5. Russia
    • 10.4.6. Italy
    • 10.4.7. Rest of Europe
  • 10.5.Market Attractiveness Analysis
    • 10.5.1. By Test
    • 10.5.2. By End User
    • 10.5.3. By Country
  • 10.6. Prominent Trends

11. Asia Pacific Non-Invasive Prenatal Testing Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Basis Point Share (BPS) Analysis By Country
    • 11.1.2. Y-o-Y Growth Projections By Country
  • 11.2.Market Value Forecast By Test, 2024-2033
    • 11.2.1. Panel 1 Test
    • 11.2.2. Panel 2 Test
    • 11.2.3. Panel 3 Test
  • 11.3.Market Value Forecast By End User, 2024-2033
    • 11.3.1. Hospitals
    • 11.3.2. Diagnostic Laboratories
    • 11.3.3. Maternity Centers
  • 11.4.Market Value Forecast By Country, 2024-2033
    • 11.4.1. Japan
    • 11.4.2. China
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. ASEAN
    • 11.4.6. Rest of APAC
  • 11.5.Market Attractiveness Analysis
    • 11.5.1. By Test
    • 11.5.2. By End User
    • 11.5.3. By Country
  • 11.6. Prominent Trends

12. Middle East and Africa Non-Invasive Prenatal Testing Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Basis Point Share (BPS) Analysis By Country
    • 12.1.2. Y-o-Y Growth Projections By Country
  • 12.2.Market Value Forecast By Test, 2024-2033
    • 12.2.1. Panel 1 Test
    • 12.2.2. Panel 2 Test
    • 12.2.3. Panel 3 Test
  • 12.3.Market Value Forecast By End User, 2024-2033
    • 12.3.1. Hospitals
    • 12.3.2. Diagnostic Laboratories
    • 12.3.3. Maternity Centers
  • 12.4.Market Value Forecast By Country, 2024-2033
    • 12.4.1. GCC Countries
    • 12.4.2. South Africa
    • 12.4.3. Rest of MEA
  • 12.5.Market Attractiveness Analysis
    • 12.5.1. By Test
    • 12.5.2. By End User
    • 12.5.3. By Country
  • 12.6. Prominent Trends

13. Competition Landscape

  • 13.1. Competition Dashboard
  • 13.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 13.2.1. Ariosa Diagnostics, Inc.
    • 13.2.2. Berry Genomics Co. Ltd.
    • 13.2.3. BGI Diagnostics
    • 13.2.4. Illumina, Inc.
    • 13.2.5. LifeCodexx AG
    • 13.2.6. Natera, Inc.
    • 13.2.7. Sequenom Laboratories
    • 13.2.8. Quest Diagnostics, Inc.

14. Assumptions and Acronyms Used

15. Research Methodology